PEA
Palmitoylethanolamide
TL;DR
PEA (palmitoylethanolamide) is an endogenous fatty acid amide with reasonably consistent meta-analytic evidence for reducing chronic and neuropathic pain, with an unusually clean safety record.
Ideal For
- People with neuropathic pain such as sciatica or diabetic neuropathy
- Those seeking a pain adjunct with a very low side effect burden
- People reducing NSAID use under clinician guidance
Avoid If
- You are pregnant or breastfeeding, due to absent data
- You expect it to replace prescribed neuropathic pain medication
- You need rapid relief, as onset takes weeks
Frequently Asked Questions
Overview
Palmitoylethanolamide is produced naturally in the body as part of the endocannabinoid-like signalling system. It does not bind CB1 or CB2 directly; it activates PPAR-alpha and reduces mast cell and glial activation, which is why it is described as an ALIAergic rather than an analgesic drug. Pooled analyses of roughly 10 to 15 randomised and controlled trials, mostly Italian, report clinically meaningful pain reductions in sciatica, diabetic neuropathy, carpal tunnel and pelvic pain, typically 1.5 to 2 points more than control on a 10-point scale over 3 to 8 weeks, with a dose-dependent pattern. The main caveats are that most trials come from one research network, several used non-blinded designs, and the micronised or ultramicronised formulations that performed best are patented products. Tolerability across trials is excellent, with adverse event rates indistinguishable from placebo.
How It Works
- Activates PPAR-alpha, suppressing transcription of inflammatory genes
- Downregulates mast cell degranulation in peripheral nerve tissue
- Reduces microglial and astrocyte activation in the spinal cord, dampening central sensitisation
- Exerts an entourage effect, raising anandamide activity indirectly without binding CB receptors
Benefits & Outcomes
No linked outcomes yet. Research is ongoing.
Supporting Research8 studies
N-Palmitoyl Ethanol Amide Pharmacological Treatment in Patients With Nonsurgical Lumbar Radiculopathy
Chirchiglia D, Della Torre A, Signorelli F
Ultramicronised palmitoylethanolamide reduced pain intensity in patients with non-surgical lumbar radiculopathy, with benefit maintained through long-term follow-up and no significant adverse events reported.
Efficacy and Safety of the Combination of Palmitoylethanolamide, Superoxide Dismutase, Alpha Lipoic Acid, Vitamins B12, B1, B6, E, Mg, Zn and Nicotinamide for 6 Months in People with Diabetic Neuropathy
73 patients randomised; active combination improved pain score, B12 levels, vibration perception threshold and sural nerve conduction versus placebo.
Ultramicronized palmitoylethanolamide in spinal cord injury neuropathic pain: a randomized, double-blind, placebo-controlled trial
Andresen SR, Bing J, Hansen RM +7 more
Ultramicronized PEA did not reduce neuropathic pain intensity more than placebo
Palmitoylethanolamide in the Treatment of Chronic Pain: A Systematic Review and Meta-Analysis of Double-Blind Randomized Controlled Trials
Lang-Illievich K, Klivinyi C, Rumpold-Seitlinger G +2 more
Palmitoylethanolamide significantly reduced pain intensity compared with placebo or active comparators, with a favorable adverse event profile
Efficacy of Palmitoylethanolamide for Pain: A Meta-Analysis
Artukoglu BB, Beyer C, Zuloff-Shani A +2 more
PEA reduced pain scores significantly more than control, with greater effect at longer treatment durations
Extended Treatment with Micron-Size Oral Palmitoylethanolamide (PEA) in Chronic Pain: A Systematic Review and Meta-Analysis
Schweiger V, Martini A, Bellamoli P +8 more
Prolonged treatment with micron-size PEA was associated with sustained reductions in pain intensity without safety signals
Palmitoylethanolamide in the Treatment of Chronic Pain Caused by Different Etiopathogenesis
Gatti A, Lazzari M, Gianfelice V +3 more
Pain intensity decreased significantly from baseline during PEA add-on therapy across neuropathic, mixed and nociceptive pain groups
Palmitoylethanolamide in Fibromyalgia: Results from Prospective and Retrospective Observational Studies
Del Giorno R, Skaper S, Paladini A +2 more
Adding PEA to duloxetine and pregabalin produced further reductions in pain scores and tender points
Safety Information
Potential Side Effects
Adverse event rates in trials match placebo. Occasional mild GI upset or drowsiness reported.
Contraindications
None established; data are absent in pregnancy and childhood.
Drug Interactions
- No clinically significant interactions documented
- Theoretically additive with other analgesics, which is usually the intent
Pregnancy & Breastfeeding
Pregnancy: insufficient_data
Breastfeeding: insufficient_data
Dosage Guidelines
Dosage Used in Studies
Consult healthcare provider
Forms Compared
Food & Timing
With a fat-containing meal; PEA is lipophilic and poorly water soluble.
Medical Disclaimer
The information provided on this website is for educational and informational purposes only and is not intended as a substitute for professional medical advice, diagnosis, or treatment. Always seek the advice of your physician or other qualified health provider with any questions you may have regarding a medical condition or before starting any supplement regimen.
Individual results may vary. The statements on this website have not been evaluated by the Food and Drug Administration. Products and information are not intended to diagnose, treat, cure, or prevent any disease.